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Abstract:
Neuronal apoptosis has been shown to be associated with the development of tolerance to morphine. In the present study, we investi-
gated the effect of intracerebroventricular (icv) administration of an inhibitor of glutamate release, riluzole, on morphine-induced
apoptosis in the rat cerebral cortex. Various groups of rats received either morphine (intraperitoneally, ip) and vehicle (icv) or mor-
phine (ip) and different doses of riluzole (icv) once per day for 8 days. An in situ terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end-labeling (TUNEL) method was used as an apoptosis assay. Levels of the anti-apoptotic factors Bcl-2 and
HSP70 and the pro-apoptotic agent caspase-3 were evaluated by immunoblotting. The glutamate concentration in the cerebral cortex
was measured by high performance liquid chromatography (HPLC). The results showed that icv administration of riluzole decreased
the number of apoptotic cells in the cerebral cortex compared with the control group, which was treated with morphine (ip) and 1%
Tween 80 in 0.9% normal saline (icv). The levels of the anti-apoptotic proteins Bcl-2 and HSP70 were higher in the riluzole groups
than in the control. Furthermore, co-administration of riluzole with morphine significantly decreased caspase-3 protein levels and
glutamate content of the cerebral cortex compared with the control. In conclusion, we found that icv administration of riluzole at-
tenuates morphine-induced apoptosis in the cerebral cortex after the development of morphine tolerance.
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Introduction
Although opioid drugs such as morphine are indispen-
sable in the clinical management of pain, their re-
peated use can lead to the development of analgesic
tolerance and physical dependence. Opioid tolerance
manifests as a loss of agonist potency and as a shift of
the dose-response curve to the right. Many neuro-
transmitter systems are implicated in the development
of morphine tolerance elicited by prolonged morphine
exposure. During the past decades, many studies have
focused on the roles of excitatory amino acid recep-
tors in the development of tolerance to the antino-
ciceptive action of morphine. Numerous studies have
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demonstrated that a variety of N-methyl-D-aspartate
(NMDA) receptor antagonists and blockers have the
ability to inhibit the development of opiate tolerance
and dependence [2, 12, 14, 15, 33]. Other studies have
shown that activation of NMDARs can lead to neuro-
toxicity under many circumstances [26, 27]. For in-
stance, peripheral nerve injury has been shown to ac-
tivate spinal cord NMDARs, which results in not only
intractable neuropathic pain but also neuronal cell
death by means of apoptosis [20, 35]. In addition, it
has been shown that, in vivo, neuronal apoptosis oc-
curs in the rat’s spinal cord and dorsal raphe nucleus
after chronic morphine treatment [7, 17, 21]. Our
more recent studies demonstrated that prolonged mor-
phine administration induces up-regulation of pro-
apoptotic elements such as caspase-3 and down-
regulation of the anti-apoptotic factors Bcl-2 and
HSP70 in the rat cerebral cortex and spinal cord [16,
17]. Importantly, up-regulation of caspase-3 and Bax
was inhibited when morphine was co-administered
with the noncompetitive NMDAR antagonist MK-801,
thereby supporting a link between NMDAR activa-
tion and intracellular changes in caspase-3 and Bax in
response to prolonged morphine administration [21].
One portion of our recently published finding, which
is reproduced in Figure 1, indicated that riluzole (2-
amino-6-[trifluoromethoxy]benzothiazole), an antiglu-
tamatergic agent, decreases the development of toler-
ance, shifting the first day of established tolerance
from the 8  day in the control group (treated intraperi-
toneally, ip, with morphine and 1% Tween 80, icv) to
the 13  day [13]. Riluzole interferes with responses
mediated by excitatory amino acids, even though it
does not interact with any known binding sites on the
NMDA, kainate or AMPA glutamate receptors [9].
The neuroprotective effect of riluzole, which has been
shown both in vivo and in vitro, is believed to be
beneficial in various neurodegenerative diseases and
amelioration of trauma and stroke [1, 10]. In the pres-
ent study, we were interested in investigating the ef-
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Fig. 1. Effect of daily icv injection of riluzole (20, 40 and 80 µg/10 µl/rat) on tolerance to the analgesic effect of morphine. Each bar represents
the mean of %MPE (maximal possible effect) ± SEM for 8 rats. A Student’s t-test was used to compare the statistical differences between each
treatment and saline group. A one-way ANOVA followed by Tukey test was used to analyze the statistical significances between the treated and
control groups. A p-value of less than 0.05 was considered to be significant in all analyses. * p < 0.05; ** p < 0.01; *** p < 0.001 when compared
with saline group. # p < 0.001 when compared with control (M + 1% Tween 80). The arrow represents the first day of morphine tolerance. M =
Morphine, Rilu = Riluzole [13]
fect of intracerebroventricular (icv) administration of
riluzole on morphine-induced apoptosis in the rat
cerebral cortex after the development of tolerance to
the analgesic effects of morphine.
Materials and Methods
Drug treatment
Morphine sulfate (Temad Co., Iran; 10 mg/kg, ip) was
dissolved in sterile 0.9% normal saline and injected ip
using 1-ml insulin syringes. Riluzole (Sigma-Aldrich,
Inc.; 20, 40 and 80 µg/10 µl/rat) was dissolved in 1%
Tween 80 in sterile 0.9% normal saline and infused
icv using a Hamilton syringe. In addition, two groups
of animals received saline and vehicle or riluzole
(80 µg/10 µl/rat) alone. The volume of infusion was
10 µl at a rate of 10 µl/min for each rat.
Animals
Male Wistar rats weighing 250–300 g were kept in
a temperature-controlled room (24 ± 0.5°C) and were
maintained on a 12-h light/dark cycle (light on at
08:00 h) with free access to food and water. All ex-
periments were executed in accordance with the
Guide for the Care and Use of Laboratory Animals
(National Institutes of Health Publication No. 85–23,
revised 1985) and were approved by the research and
ethics committee of the Tabriz University of Medical
Sciences. In total, 72 rats were used (6 rats per group
for TUNEL and western blot analysis).
Icv cannula implantation
Rats were anesthetized with sodium pentobarbital
(50 mg/kg, ip; Merck, Germany) and were stereotaxi-
cally implanted with a stainless steel guide cannula
(23 gauge) into the lateral cerebral ventricle with coor-
dinates of –0.8 mm posterior, –1.3 mm midline to lat-
eral and 3.5 mm ventral with respect to bregma [25].
A stainless steel guide (30 gauge) was placed into
the guide cannula as a dummy cannula to maintain
patency. After surgery, a recovery period of 7 days
was allowed before the commencement of the central
and systemic injections. Morphine and riluzole injec-
tions were started at day 8 after cannula implantation.
Tissue preparation
For the in situ TdT-mediated dUTP-biotin nick end-
labeling (TUNEL) assay, all animals (n = 6) received
the same treatment regimen such as the behavioral
groups in our previous study [13]. On the 9  day (one
day after tolerance completion in the control group),
2 h after the last dose of vehicle or treatment, the ani-
mals were euthanized with pentobarbital and perfused
with phosphate buffered saline (PBS). Cerebral cor-
texes were immediately dissected and fixed in 10%
(v/v) formaldehyde (Merck, Germany; pH adjusted to
7.0 with NaOH) for 3 days. The tissues were then em-
bedded in paraffin. To evaluate a possible association
between morphine tolerance and apoptosis, we used
a group of rats that received morphine along with rilu-
zole at a dose of 80 µg/10 µl/rat, which was the most
effective dose of riluzole for inhibition of morphine
tolerance. One day after tolerance completion in this
group (on day 14 ) and 2 h after the last dose of vehi-
cle or treatment, the cerebral cortexes of the rats were
removed and prepared as described above.
Detection of apoptotic cells
After fixation and paraffin embedding, sections
(3 µm) were cut with a microtome (Leitz, Germany).
For the TUNEL assay, an in situ Cell Death Detection
kit (Roche Applied Science, Cat # 11 684 817 910)
was used. After deparaffinization, the tissue sections
were stained according to the manufacturer’s instruc-
tions. Briefly, deparaffinized and rehydrated sections
were pretreated with proteinase K (Roche, Germany)
for 30 min at 37°C. Then, the sections were exposed
to the TUNEL reaction mixture, which contains ter-
minal deoxynucleotidyl transferase and nucleotides
including fluorescein isothiocyanate-labeled dUTP
(37°C). After 60 min, an anti-fluorescein peroxidase
(POD)-linked antibody was added, followed by incu-
bation for 30 min at 37°C. Finally, the reaction prod-
uct was visualized by 3,3-diaminobenzidine tetrahy-
drochloride (DAB) incubation for 15 min at RT, and
the slides were then counterstained with methylene
blue. A subpopulation of apoptotic cells, scattered
throughout the tissue section, was intensely stained
(brown) by the TUNEL treatment; their numbers were
analyzed using a Zeiss Axiovert 100 light microscope
(100× objective) over 30 fields.
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Western blot analysis of Bcl-2, HSP70 and
caspase-3
For western blotting, rats (n = 6) were rapidly (< 1 min)
sacrificed, and the cerebral cortex segments were re-
moved, cleaned and frozen in liquid nitrogen. Subse-
quently, the tissue samples were homogenized in lysis
buffer (500 mM Tris-HCl, pH 7.4, 150 mM NaCl,
EDTA 0.5 mM, N-octyl -D-glucopyranoside 1.5%
w/v) containing a complete protease inhibitor cocktail
tablet (Roche Cat # 04 693 132 001). The protein
quantification for each loading lane was estimated by
a protein assay with absorbance at 280 nm. Lysates
(20 µg protein) were resolved by SDS-PAGE (12%)
for Bcl-2 and HSP70 and by SDS-PAGE (15%) for
caspase-3. Next, the lysates were transferred to poly-
vinylidene difluoride (PVDF) filters (Millipore, Bed-
ford, MA, USA), which were blocked with 5% milk and
incubated overnight at 4°C with the following primary
antibodies, all of which were purchased from Abcam:
caspase-3 (18-20 kDa), 1:500, Cat # ab2302; Bcl-2
(26-29 kDa), 1:1000, Cat # ab16904; HSP 70 (70
kDa), 1:5000, Cat # ab6535; and -actin (42 kDa),
1:1000, Cat # 8226. Subsequently, PVDF membranes
were incubated for 1 h at room temperature with an
HRP-conjugated secondary antibody (1:10,000). The
blots were then visualized with an enhanced chemilu-
miniscence (ECL) detection kit/system for 1 min and
were exposed to Hyperfilm (Roche) for 30 s to 5 min.
Finally, the developed films were scanned, and the
density of immunoreactive bands was measured using
ImageJ software and normalized to the internal control
bands. -Actin was used as a loading control. For west-
ern blotting, differences in the image density were ana-
lyzed by a one-way analysis of variance (ANOVA)
(multiple groups) followed by a Tukey test.
High performance liquid chromatography
(HPLC) analysis of glutamate
To determine the levels of the amino acid neurotrans-
mitter glutamate, HPLC was employed. Tissue sam-
ples from rats (n = 6) were homogenized, and protein
determination was performed. Subsequently, the ho-
mogenates were spun at 4°C for 10 min at 10,000 × g.
The chromatograph was a KNAUER (Berlin, Ger-
many) HPLC instrument. The system included a qua-
ternary pump, a RF-551 fluorescence detector (FLD)
and an autosampler (Spark, Triatlon), which was con-
trolled by Chromgate software. The analytical column
used was a reverse phase Hypersil ODS column (250
× 4.0 mm, 5 µm particle size) at room temperature.
For the chromatographic separation, the mobile phases
consisted of 8% acetonitrile in 12.5 mM phosphate
buffer, pH 7.2, with an o-phthalaldehyde (OPA) de-
rivative of glutamate eluted at a gradient flow rate of
1 ml/min for 8 min and 2 ml/min for 12 min, and the
detection was carried out with 330 nm and 460 nm as
the excitation and emission wavelengths, respectively.
Glutamic acid was used as a standard. Solutions of
glutamic acid (0.75, 1.5, 3, 6 and 12 µg/ml) were in-
jected into the HPLC instrument, and a calibration
curve was plotted. A 2.5% solution of supernatant in
distilled water was used for derivatization and deter-
mination of glutamate. The level of glutamate was
calculated by comparing the peak areas with those of
the standards, and the values were expressed as
µmol/100 mg protein [23].
Data analysis
The histological data (cell counting) from cerebral
cortex sections were averaged and are expressed as
the means ± SEM. Data from the western blots are ex-
pressed as % of control (morphine, ip, and 1% Tween
80, icv), and data from HPLC are expressed as the
means ± SEM. Student’s t-test was used to compare
the means of two groups, and a one-way analysis of
variance (ANOVA) followed by Tukey test was used
to compare the means of multiple treatment groups;
p-values of less than 0.05 were considered to be sig-
nificant.
Results
The presence of apoptotic cells was evidenced
by TUNEL staining
The TUNEL method was used to identify apoptotic
cells. In the control group (morphine, ip, and 1%
Tween 80 in 0.9% normal saline, icv), the number of
TUNEL-positive cells significantly (p < 0.001) in-
creased in cerebral cortex in comparison with vehicle-
treated animals (Fig. 2), thereby indicating that there
was an increased basal level of apoptosis in morphine-
treated animals. The average number of TUNEL-
positive cells in the cerebral cortex was significantly
reduced in the riluzole groups (40 and 80 µg/10 µl/rat)
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Fig. 2 (A) Tissue sections from rat cerebral cortex were prepared and assayed with an In Situ Cell Death Detection Kit, POD. Slides were coun-
terstained with methylene blue. Representative photos illustrate the subpopulation of apoptotic cells, which are scattered throughout the tissue
section and were intensely stained (brown) by the TUNEL treatment. Slides were analyzed with a light microscope (100   objectives).
(A) a: Morphine + 1% Tween 80, b: Saline + 1% Tween 80, c: Morphine + Riluzole (20 µg/10 µl/rat), d: Morphine + Riluzole (40 µg/10 µl/rat),
e: Morphine + Riluzole (80 µg/10 µl/rat), f: Riluzole (80 µg/10 µl/rat). (B) Quantification of apoptotic cells. The data represent the mean ± SEM
number of apoptotic (TUNEL-positive) cells in 30 fields, which were counted at a magnification of 100  with a light microscope. A one-way
ANOVA followed by Tukey test was used to analyze the statistical significances. A p-value of less than 0.05 was considered to be significant for
all analyses,* p < 0.05; ** p < 0.01; *** p < 0.001 when compared with the control group (M + Tween 80 1%). S = Saline, M = Morphine, Rilu = Ri-
luzole, AT = After tolerance
compared with those in the control group (morphine,
ip, and 1% Tween 80, icv). There were significant dif-
ferences in the number of TUNEL-positive cells be-
tween animals that had received vehicle or riluzole
without morphine versus those that received morphine
(p < 0.001). Animals treated with the higher dose of ri-
luzole (80 µg/10 µl/rat) had fewer TUNEL-positive
cells than animals treated with the lower doses. The
group that received morphine and riluzole (80 µg/10 µl/
rat) for 13 days had developed tolerance; they showed
an increase in the number of apoptotic cells compara-
ble to that seen in control conditions (morphine, ip, and
1% Tween 80, icv).
Changes in the Bcl-2, HSP 70 and caspase-3
protein content of the cerebral cortex
Our results show that after the development of mor-
phine tolerance, levels of the anti-apoptotic factors
Bcl-2 (p < 0.01) and HSP70 (p < 0.001) decreased
significantly, while expression of the pro-apoptotic
protein caspase-3 increased in the cerebral cortex
(Figs. 3–5). All three doses of riluzole (20, 40 and 80
µg/10 µl/rat) increased the amount of HSP70 signifi-
cantly (p < 0.001) while only the highest dose of rilu-
zole (80 µg/10 µl/rat) was able to significantly attenu-
ate the morphine-induced down-regulation of Bcl-2
(p < 0.01). In addition, the results show that riluzole,
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Fig. 3. Effect of icv riluzole (20, 40 and 80 µg/10 µl/rat) on morphine-induced changes in intracellular Bcl-2 levels (n = 5 rats per group for sepa-
rate sample collections). (A) Representative autoradiographs of western blots illustrate a down-regulation in the levels of Bcl-2 protein (26 kDa)
in rats receiving morphine (M + 1% Tween 80) daily for 9 days compared with the corresponding S + 1% Tween 80 group. Riluzole (80 µg/
10 µl/rat) increased the amount of Bcl-2 protein in combination with morphine. (B) The statistical analysis showed differences among the vari-
ous groups in the gray density obtained for the bands on the Bcl-2 western blot. A one-way ANOVA followed by Tukey test were used to analyze
the statistical significances. A p-value of less than 0.05 was considered to be significant for all analyses, * p < 0.05, ** p < 0.01 compared with
the corresponding control group (morphine, ip, and 1% Tween 80, icv). S = Saline, M = Morphine, Rilu = Riluzole, AT = After tolerance
at doses of 40 and 80 µg/10 µl/rat significantly de-
creased the levels of the pro-apoptotic factor caspase-3
in the cerebral cortex compared with the control (mor-
phine, ip, and 1% Tween 80, icv) (p < 0.05), as shown
in the western blots in Figure 5.
Effect of riluzole on glutamate concentration in
the cerebral cortexes of morphine-treated rats
The results presented in Table 1 show that chronic ad-
ministration of morphine (10 mg/kg, ip) for 9 days in-
duced a significant increase in glutamate concentra-
tion in the cerebral cortex of morphine-tolerant rats
(p < 0.001). On the other hand, our findings indicate that
icv administration of riluzole (40 and 80 µg/10 µl/rat)
concomitantly with morphine was able to attenuate
this elevation in glutamate concentration (p < 0.001).
Discussion
The purpose of this study was to explore the cellular
mechanism of riluzole’s effects on tolerance to mor-
phine. Our findings are consistent with the idea that
morphine-induced tolerance and apoptosis is attenu-
ated by icv administration of riluzole. The cellular
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Fig. 4. Effect of icv riluzole (20, 40 and 80 µg/10 µl/rat) on morphine-induced changes in intracellular HSP 70 levels (n = 5 rats per group for
separate sample collections). (A) Representative autoradiographs of western blots illustrate a down-regulation of the levels of HSP 70 protein
in rats receiving morphine (M + 1% Tween 80) daily for 9 days compared with the corresponding S + 1% Tween 80 group. Riluzole (40 and
80 µg/10 µl/rat) increased the amount of HSP 70 protein. (B) The statistical analysis showed differences in the gray density from the bands on
the western blot of HSP 70 among the various groups. A one-way ANOVA followed by Tukey test were used to analyze the statistical signifi-
cances. A p-value of less than 0.05 was considered to be significant for all analyses, *** p < 0.001 compared with the corresponding control
group (morphine, ip, and 1%Tween 80, icv). S = Saline, M = Morphine, Rilu = Riluzole, AT = After tolerance
mechanism underlying the development of morphine
tolerance remains controversial. It has been demon-
strated that certain addictive drugs, such as morphine,
can induce apoptosis in both in vitro and in vivo stud-
ies [7, 17, 28, 30]. More recently, we showed in vivo
that neuronal apoptosis occurs in the rat spinal cord
after chronic morphine treatment and is associated
with an elevation in caspase-3 levels and a decrease in
the amounts of the anti-apoptotic agents Bcl-2 and
HSP70, suggesting that chronic morphine administra-
tion may lead to changes within the central nervous
system (CNS) [17]. The results of the present study
indicate that prolonged exposure to morphine induces
apoptotic cell death in the cerebral cortex, which con-
tributes, at least in part, to the behavioral manifesta-
tion of morphine tolerance. Our recent study showed
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Tab. 1. Concentration of glutamate in cerebral cortex of rat
Treatment Glutamate concentration
(umol/100 mg protein)
S + 1% Tween 80 310 ± 9.69***
M +1% Tween 80 478.5 ± 5.2
M + Rilu (20 µg/10 µl/rat) 456.6 ± 9.75
M + Rilu (40 µg/10 µl/rat) 449.8 ± 6.51*
M + Rilu (80 µg/10 µl/rat) 405.71 ± 9.39***
Rilu (80 µg/10 µl/rat) 304.8 ± 7.50***
Each data represents the mean ± SEM for 5 rats. One-way ANOVA
followed by Tukey’s test was used to analyze the statistical signifi-
cances. A p-value less than 0.05 was considered to be significant in
all analyses, * p < 0.05, *** p < 0.001 when compared to control (M +
1% Tween 80) group. S = Saline, M = Morphine, Rilu = Riluzole
Fig. 5. Effect of icv riluzole (20, 40 and 80 µg/10 µl/rat) on morphine-induced changes in intracellular caspase-3 content (n = 5 rats per group
for separate sample collections). (A) Representative autoradiographs of western blots illustrate up-regulation of the levels of caspase-3 protein
(19 kDa) in rats receiving morphine (M + 1% Tween 80) daily for 9 days compared with the corresponding S + 1% Tween 80 group. (B) The sta-
tistical analysis showed differences in the gray density obtained for the bands on the western blot representing caspase-3 protein among dif-
ferent groups in the cerebral cortex. A one-way ANOVA followed by Tukey test were used to analyze the statistical significances. A p-value of
less than 0.05 was considered to be significant for all analyses, * p < 0.05 compared with the corresponding control group (morphine, ip, and
1% Tween 80, icv). S = Saline, M = Morphine, Rilu = Riluzole, AT = After tolerance
that chronic administration of morphine for 8 days in-
duced tolerance to its analgesic effects, while admini-
stration of riluzole (80 µg/10 µl/rat) decreased the de-
velopment of this tolerance by shifting the first day of
established tolerance from the 8  to the 13  day (Fig.
1). The results indicated that there was a significant
shift to the right in the dose-response curve as well as
an increase in the antinociceptive 50% effective dose
(ED) of morphine for animals who received mor-
phine also compared with those that received mor-
phine and riluzole (80 µg/10 µl/rat). Moreover, ad-
ministration of riluzole (80 µg/10 µl/rat) alone was
without a significant analgesic effect, so this result is
not related to morphine-independent analgesic effects
of riluzole [13]. Furthermore, it has been demon-
strated that both morphine tolerance and the associ-
ated neuronal apoptosis share a common cellular
mechanism mediated, at least in part, by the
NMDAR, because MK-801 blocks both tolerance and
apoptosis [21]. Activation of NMDARs, in contrast,
initiates intracellular pathways leading to apoptotic
cell death. Our results, in agreement with those of oth-
ers, indicate that chronic morphine administration sig-
nificantly increases apoptosis in the rat cerebral cor-
tex (p < 0.001). On the other hand, co-administration
of riluzole delayed the onset of morphine-induced
apoptosis and significantly decreased the average
number of TUNEL-positive cells (p < 0.01). This
finding is in line with our recent results concerning
the lumbar region of the spinal cord [17]. In addition,
we found that the group that received morphine and
riluzole (80 µg/10 µl/rat) for 13 days had developed
tolerance; they showed an increase in the number of
apoptotic cells, as under control conditions. This re-
sult indicates that after the completion of tolerance in
both the control (morphine, ip, and 1% Tween 80, icv)
and the treated groups, apoptosis had already devel-
oped. Other studies have demonstrated that chronic
treatment of rats with morphine (to induce tolerant
and dependent states) is associated with a remarkable
differential modulation of two key proteins involved
in the regulation of programmed cell death in the
brain; namely, there is an up-regulation of the pro-
apoptotic Fas receptor, as well as intracellular pro-
apoptotic elements such as caspase-3, combined with
an opposing moderate down-regulation of the anti-
apoptotic oncoprotein Bcl-2 [4, 21].
Our results in this study were in line with previous
reports indicating that morphine treatment can de-
crease the Bcl-2 content of the brain [4, 16]. Riluzole
(80 µg/10 µl/rat), on the other hand, can increase the
Bcl-2 level in the cerebral cortex when given in com-
bination with morphine.
Previous studies have demonstrated that HSP70
proteins participate in protein folding and transport,
refolding of denatured proteins and cellular protection
from apoptosis. HSP70 protects cells from apop-
totic/necrotic death, which normally occurs after heat
shock, exposure to tumor necrosis factor-, oxidative
stress, ceramide, anti-cancer drugs, radiation or nitric
oxide [11, 22]. HSP70 has been reported to inhibit
heat shock-induced apoptosis downstream of cyto-
chrome c release but upstream of caspase-3 activation
[19]. Our results, in agreement with data from other
groups showing that morphine significantly decreased
HSP70 levels in rat neurons [8], demonstrated that the
HSP70 content of the cerebral cortex fell after mor-
phine chronic administration in morphine tolerant
rats. On the other hand, all three doses of riluzole sig-
nificantly increased the amount of HSP70 (p < 0.001).
The parallel increases in two anti-apoptotic factors,
Bcl-2 and HSP70, represent a possible cellular
mechanism for riluzole-mediated neuroprotection.
Morphine treatment also increased the caspase-3
content of the cerebral cortex, and the statistical
analysis revealed that riluzole (at doses of 40 or
80 µg/10 µl/rat) was able to prevent the morphine-
induced increase in caspase-3. Previous studies have
demonstrated that chronic morphine administration
can increase glutamate release in the CNS [3, 33]. In
cerebrocortical nerve terminals, riluzole inhibits glu-
tamate release by reducing Ca  influx through P/Q
type Ca  channels. Importantly, excessive release and
accumulation of glutamate, which is associated with
an increase in the level of intracellular calcium, plays
an important role in CNS injury and neurodegenera-
tive diseases [34]. It has also been reported that high
concentrations of riluzole can attenuate excitatory
amino acid receptor activation and decrease the excit-
ability of the postsynaptic cell membrane [5, 6]. In
agreement with previous studies, our results showed
that morphine increased the level of glutamate in the
cerebral cortex, while co-administration of riluzole
(40 and 80 µg/10 µl/rat) significantly attenuated the
elevation of the glutamate concentration. Although
glutamate plays different roles in glutamatergic and
GABAergic neurons, and measuring the overall gluta-
mate content in the brain is not specific enough to in-
dicate the presence of glutamate-induced excitotoxic-
ity, these results confirm previous findings and sug-
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gest that this decrease in glutamate is a possible factor
in the neuroprotective and antiapoptotic effects of ri-
luzole.
Morphine treatment has been demonstrated to lead
to oxidative stress in various cells [24, 29] and has
been proposed to induce macrophage injury in mice
and humans [18]. Riluzole, apart from its role as an
antiglutamatergic agent, has been reported to have an-
tioxidant effects and could protect dopaminergic neu-
rons against oxidative stress by reducing lipid peroxi-
dation and ATP consumption [31, 32]. Thus, the anti-
oxidant properties of riluzole may be important for its
protection against morphine-induced apoptosis; this
idea needs to be further investigated.
In conclusion, we found that icv administration of
riluzole attenuates morphine-induced apoptosis in the
cerebral cortex after the development of tolerance to
morphine’s analgesic effects. In addition, riluzole de-
creased the morphine-induced elevation in glutamate
concentration in the rat cerebral cortex. However, fur-
ther studies are required to clarify the other mecha-
nisms underlying riluzole’s effects on morphine-
induced tolerance.
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